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ABSTRACT
Based on 108 differentially expressed genes between carcinoma-associated 
fibroblasts (CAFs) and paired normal colonic fibroblasts we recently reported, a 
5-gene classifier for relapse prediction in Stage II/III colorectal cancer (CRC) was 
developed. Its predictive value was validated in datasets GSE17538, GSE33113 
and GSE14095. An additional validation was performed in a metacohort (n=317) 
and 142 CRC patients by means of RT-PCR. The 5-gene classifier was significantly 
associated with increased relapse risk and death from CRC across all validation series 
of Stage II/III patients used. Multivariate Cox regression analyses confirmed the 
independent prognostic value of the stromal classifier (HR=2.67; P=0.002). Post-
test probabilities provided evidence of the suitability of the 5-gene classifier in 
clinical practice, identifying a subgroup of Stage-II patients who were at high risk 
of relapse. Moreover, the a priory worst prognosis mesenchymal subtype of tumours 
can be stratified according to the physiological status of their carcinoma-associated 
fibroblasts. In conclusion the CAFs-derived 5-gene classifier provides more accurate 
information about outcome than conventional clinicopathological criteria and it could 
be useful to take clinical decisions, especially in Stage II. Additionally, the classifier 
put into relevance the CAF’s intratumoral heterogeneity and might contribute to find 
relevant targets for depleting adequate CAFS subtypes.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common 
cancer types in men and women worldwide, with more 
than one million new cases recorded annually [1]. The 
difference in prognosis between early and late stages can 
vary from a five-year survival rate of 93% at Stage-I, to 
8% at Stage-IV [2]. For Stage-III patients, post-surgical 
adjuvant chemotherapy is the standard of care [3]. 
Although most Stage-II patients are cured by surgery 
alone, a proportion of them are at high risk of relapse, 
as determined by clinical and pathological evaluation 
(advanced T stage, few examined lymph nodes, tumor 
perforation and low tumor differentiation) and are 
candidates for adjuvant chemotherapeutic treatment [4]. 
However, some patients whose clinical factors suggest 
that they do not have a higher risk of relapse based on 
clinical factors still relapse, while, on the other hand, 
approximately 40% of patients with Stage-III CRC 
enrolled in surgery-only groups did not recur in five 
years even without adjuvant treatment [5]. These facts 
demonstrate that the traditional staging system is not 
sufficient to identify those patients with Stage-II CRC 
who carry a high risk of poor outcomes, and this may lead 
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to potential under- or over-treatment in many situations. 
Identification of new biomarkers to improve prediction 
of high-risk patients with Stage-II CRC and consequently 
improved individualized cancer care are needed [6].
Many studies have used gene expression profiling 
to predict the risk of poor outcome in breast [7], lung [8, 
9] and prostate [10] cancers, and many other tumor types. 
In CRC, several studies have developed gene-expression 
prognostic signatures to classify patients according to their 
relapse risk [11]. The Oncotype-DX test [12] and Coloprint 
[13, 14] are now available for Stage-II CRC patients. More 
recently, an effort to molecularly characterize colorectal 
cancer has been made [15, 16], emphasizing the high 
degree of inter-tumor heterogeneity of this entity [17, 18]. 
Adding further to its complexity, it features intra-tumor 
heterogeneity, whereby the balance between tumor and 
stroma and their respective transcriptional status play a 
crucial role. In that sense, the response of fibroblasts to 
TGFβ is a mainstream factor for the development of more 
aggressive tumor cells [19].
Given the importance of stromal elements in 
modulating and driving cancer progression, it is crucial 
to determine the contribution of the stroma and to 
understand the consequences of changes in this tissue 
compartment. It has been suggested that changes in 
the tumor microenvironment may benefit the tumor 
by enhancing proliferation, inducing a more invasive 
malignant phenotype, and increasing chemoresistance 
[20, 21]. These stromal changes consist of activation of 
resident fibroblasts in carcinoma-associated fibroblasts 
(CAFs), increased matrix deposition, new blood vessel 
formation and immune cell infiltration. CAFs are the 
main constituents of tumor stroma and they exist in close 
proximity to the cancer epithelium. In a previous study 
(Molecular Oncology 10.1016/j.molonc.2014.04.006), 
we defined a signature of 108 genes that are deregulated 
in CAFs from primary tumors relative to normal colonic 
fibroblasts (NCFs) from adjacent mucosa in CRC 
patients. The aim of the present work is the development 
of a stromal genetic classifier from the 108 deregulated 
genes previously reported by our group. Thus, we defined 
a 5-gene stromal classifier that could predict the risk of 
relapse in different independent datasets of whole-tumor 
samples. To extend this work, we wanted to assess the 
predictive power of these genes, analyzing expression 
levels by means of quantitative real-time PCR in a set of 
142 fresh samples in order to exploit its clinical value in a 
more amenable and reproducible technique.
RESULTS
Identification of the prognostic stromal classifier
In our previous work (Molecular Oncology 
10.1016/j.molonc.2014.04.006), we obtained a list of 
108 deregulated genes (DEG) between NCFs and paired 
CAFs, fitting the following criteria:
• having at least one associated gene;
•  mean log RMA expression >4, to exclude 
background and low-abundance probes,
•  standard deviation log RMA expression >0.1, to 
exclude low-variability probes;
• q-value <0.05;
•  >2-fold change for overexpressed genes and 
<0.5-fold change for underexpressed genes.
We previously reported the functional relationship 
of those genes in CAFs biology and the processes in 
which they are involved (Molecular Oncology 10.1016/j.
molonc.2014.04.006).
The aim here is to define a CAFs-derived classifier 
from the 108 DEG. The entire process of development 
and validation of the classifier is illustrated in Figure 1. 
The selected genes were CCL11 (downregulated in 
CAFs versus paired NCF; protective gene) and PDLIM3, 
AMIGO2, SLC7A2, ULBP2 (overexpressed in CAFs 
versus paired NCF).
In the training set, the classifier was not statistically 
associated with stage (P = 0.629), patient age (P = 0.584), 
gender (P = 0.808), tumor location (P = 0.144) or adjuvant 
treatment (P = 0.469).
The expression of classifier genes is mainly 
fibroblast-specific (Supplementary Figure 1A). To 
demonstrate that these five genes have prognostic value 
if the stroma is present in a given sample, we checked 
our signature in two independent datasets of LCM 
(Laser Capture Microscope) epithelial cell-enriched 
samples. As shown in Supplementary Figure 1B and C, 
the classifier has no predictive power over recurrence in 
GSE18105 (AUC=0.50) and GSE21510 (AUC=0.53), 
for which both datasets were enriched in epithelial cells. 
Additionally, although ULBP2 can be also expressed in 
epithelial cells, the contribution of this gene to prognosis 
is negligible, at least in the two datasets of laser capture 
enriched samples checked (Supplementary figure 1D and 
E). We also excluded a possible contribution of cells to 
the epithelial to mesenchymal transition (EMT) process 
that would account for the expression of classifier genes 
(Supplementary Figure 1F-G). Considering these results, 
we concluded that the epithelial cells did not interfere with 
EMT masking the performance of the classifier.
The 5-gene classifier identifies patients with 
colorectal cancer with poor outcome in three 
independent in silico datasets
Regarding the cut off obtained in the training dataset 
(GSE14333) to segregate patients according to relapse risk 
(3rd tertile, cut off classifier score = 1.1328; Figure 2A), 
we then chose datasets of whole tumor samples as 
validation series, thereby ensuring a certain minimum 
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Figure 1: Recurrence classifier development. The 5-gene classifier is derived from a 108-gene signature of differentially expressed 
genes (DEGs) between carcinoma-associated fibroblasts (CAFs) and paired normal colonic fibroblasts (NCFs) (Molecular Oncology 
10.1016/j.molonc.2014.04.006). To develop a prognostic classifier we obtained RMA expression values of the 108 DEGs from 135 Stage II 
and III cases (GSE14333; excluding non-recurrent patients with a follow up of < 3 years; 87 without 48 with recurrence), we used the 
random resampling procedure to maintain stage proportionality, and divided the initial 135 cases into training and test sets (66% and 33% of 
cases, respectively). The latter was not involved in gene selection in order to avoid model overfitting. Transcript cluster IDs corresponding 
to the 108 DEGs (Affymetrix GeneChip Human Gene 1.0 ST Array) between NCF and CAF were mapped to probe set IDs in GSE14333 
(Affymetrix Human Genome U133A Plus 2.0 Array). We did a univariate binary logistic regression for each gene, using recurrence as the 
dependent variable. We chose genes for which p < 0.01 to model an L1 penalized GLMNET multivariate logistic regression in the training 
set. We then ran the model with the validation dataset. We repeated this process 1000 times, obtaining 1000 classifiers. We recorded all 1000 
intermediate signatures, considering only genes and discarding β regression coefficients in order to apply the same biological relevance 
(same weight) to all genes. We ranked the percentage of times each candidate gene appeared in the signatures, selecting those present in 
> 50% of signatures for the final classifier. The selected genes were PDLIM3, AMIGO2, SLC7A2, ULBP2 and CCL11. A recurrence score 
for each sample was computed as the sum of the z-scores of each gene. No gene level parameters were estimated in order to assign the 
same biological relevance to all five genes (as detailed above), and coefficients were established as 1 for overexpressed genes in CAF vs. 
NCF (PDLIM3, SLC7A2, ULBP2 and AMIGO2; risk genes) and -1 for underexpressed genes in CAF vs. NCF (CCL11, protective gene).
The genes were firstly negatively validated in two datasets of epithelial cell-enriched samples to test their stromal specificity. 
Moreover, the classifier was validated in silico in independent datasets of whole-tumor samples and in an independent cohort of 142 cases 
of Stage II/III colorectal cancers by quantitative real-time PCR.
To conduct the Kaplan-Meier analysis, patients were segregated in two risk groups using the cut off obtained in the training dataset 
(cut off classifier score = 1.1328; third tertile; > 1.1328 high-risk of relapse; < 1.1328, low-risk of relapse). The third tertile is approximately 
the relapse prevalence in colorectal cancer (approximately 33.3%).
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Figure 2: (A) Heatmap of expression values of the 5 genes of the classifier in patients of the training dataset. The cut off 
1.1328 (the 3rd tertile of the score) segregates patients in two groups of risk. Performance of the 5-gene classifier in the validation dataset 
GSE17538, (B) (ROC curve), and (C) Kaplan-Meier analysis of disease free survival. High expression patients (yellow) have a hazard 
ratio 6.08 times higher to relapse than low expression patients (blue). (D) To confirm the prognostic stromal classifier we used another 
independent dataset (GSE14095), displaying a AUC = 0.68. No survival time information was available for this dataset in order to display 
Kaplan-Meier curves.
An additional validation (E) was performed with GSE33113 (Stage II colorectal cancer patients). (F) High expression patients 
(yellow) have a hazard ratio 2.62 times higher to relapse than low expression patients (blue), P = 0.036. In this dataset, for a unit increase 
in the classifier score, the risk of relapse increases by 1.206 (95% CI = 1.036 - 1.403; P = 0.016).
(G) Standardized expression values of the five genes in the metanalysis cohort (n=317), including GSE17538, GSE33133, GSE31595 
and GSE26892. Four genes (AMIGO2, ULBP2, PDLIM3 and SLC7A2) are significantly higher in recurrent tumors compared to non-
recurrent tumors (statistical significance assessed by the Student’s t-test).
(H) Scatter plot of the 317 patients of the meta-cohort according to the 5-gene classifier score (yellow dots recurrent patients, blue 
dots non-recurrent patients The red dotted line is the cut off obtained in the training dataset to categorize patients according to risk of 
relapse. The receiver operating characteristic curve describes the performance of the 5-gene classifier in this large cohort (I).
(J to L) Kaplan-Meier curves in the meta-cohort.
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stroma percentage (approximately >20-25%, as detailed 
at GEO). Consequently, we ascertained the performance 
of the 5-gene classifier in GSE17538 (Figure 2B and C; 
AUC=0.84; HR=6.09; P<0.0001), GSE14095 (AUC=0.68; 
Figure 2D) and GSE33113 (Stage II, Figure 2E and F; 
AUC=0.68, HR=2.62, P=0.036).
Survival information data were not available for the 
GSE14095 dataset (recurrence status only).
In silico validation: meta-cohort
We merged the previous GSE17538 and 
GSE33113 validation datasets, and added two more 
datasets, GSE31595 and GSE26892, to create a meta-
cohort of 317 patients (28 Stage-I, 176 Stage-II and 113 
Stage-III). Since the score was calculated using z-scores 
for each gene and dataset before merging, the impact of 
the centre/hospital bias was negligible. The association 
of each single gene of the classifier with the recurrence 
status is illustrated in Figure 2G and the performance of the 
classifier in predicting recurrence is depicted in Figures 2H 
and I. Therefore, according to the cut off (1.1328), 30.6% 
and 69.4% of patients with the higher 5-gene signature 
score were identified respectively as high- and low-risk. 
Low-risk patients had a 5-year DFS rate of 73%, whereas 
the rate in high-risk patients was only 36% (Figure 2J). 
Using the 5-gene signature score as a continuous variable, 
the HR increased by 1.236 (95% CI=1.15-1.33) per unit 
increase in the SD of expression. Stratifying by disease 
stage (Figures 2K and L) revealed 5-year DFS rates of 
33% in high-risk Stage-II patients, 77% in low-risk patients 
(HR=4.18, 95% CI=2.39-7.31, P<0.0001) and HR=2.18 
(95% CI=1.25-3.82, P =0.007) for high-risk Stage-III 
patients (5-year DFS rate of 33% versus 59% of low-risk).
To assess the potential utility of the 5-gene classifier 
in clinical practice we evaluated the post-test recurrence 
probabilities and compared them with the a priori 
expected prevalence (Table 2).
For this metacohort, a detailed comparison of the 
5-gene classifier with clinical factors was not possible 
because limited information across all GEO datasets 
further than age, gender and stage. Other variables such 
as tumor grade was only available for GSE17538 and 
adjuvant treatment, isolated nodes, lymphatic invasion 
were not available.
PCR validation in an independent cohort of 
142 patients
We aimed to translate the 5-gene signature score 
obtained by means of microarray technology to a 
technique that was more convenient and less subject to 
bias, such as real-time PCR. For this purpose we used a 
cohort of 142 well annotated Stage II/III colorectal cancer 
patients from our institution. Patient characteristics are 
summarized in Table 1.
Table 1. Patient demografics and clinical characteristics for the training set, in silico validation 
metacohort and real timeNAPCR validation set. 
Training setGSE14333 Validation in silico metacohort Validation PCR dataset
Cohort size 135 317 142
Gender
 Male 76 (56.3) 104 (51.2)* 80 (56.3)
 Female 59 (43.7) 99 (48.8)* 62 (43.7)
Mean age 64.38 66.91* 66.71
Stage
 Stage I NA 28 (8.8) NA
 Stage II 64 (47.4) 176 (55.5) 62 (43.7)
 Stage III 71 (52.6) 113 (35.6) 80 (56.3)
Location
 Colon 118 (87.4) NA 91 (64.1)
 Rectum 17 (12.6) NA 51 (35.9)
Grade
 Low NA NA 128 (90.1)
 High NA NA 14 (9.9)
(Continued )
Oncotarget6442www.impactjournals.com/oncotarget
Training setGSE14333 Validation in silico metacohort Validation PCR dataset
Isolated nodules
 >14 NA NA 96 (67.6)
 <14 NA NA 46 (32.4)
Adjuvant chemotherapy
 yes 69 (51.1) NA 74 (52.1)
 no 66 (48.9) NA 68 (47.9)
Recurrence
 yes 48 (35.6) 103 (32.5) 43 (30.3)
 no 87 (64.4) 214 (67.5) 99 (69.7)
Kras status
 wt NA NA 73 (51.4)
 mut NA NA 47 (33.1)
 NA NA NA 22 (15.5
MSI status
 high NA NA 19 (13.4)
 MSS NA NA 100 (70.4)
 NA NA NA 23 (16.2)
Abbreviations: NA not available or not reported by authors to GEO.
*Available only for 203 patients. % are reported in brackets.Training and validation datasets used were relatively similar in 
relation to gender, age and recurrence status. Additionally, PCR validation cohort was very similar to the training dataset 
(GSE14333), with respect to the number of patients, stage distribution and percentage of patients treated in adjuvancy. 
There were some differences involving the distribution of tumour location in the colon and rectum. A previous report by 
our group demonstrated that there are no differences at the molecular level between tumours of the colon and rectum [ 
(SanzNAPamplona R, Cordero D, Berenguer A, et al. Gene expression differences between colon and rectum tumors. Clin 
Cancer Res;17:7303NA12.).
As depicted in Figure 3A, recurrent samples clearly 
have higher classifier scores than non-recurrent samples 
(P=0.007). In this cohort, using the cut off obtained in 
the training dataset, 31% of patients were considered 
high-risk (44 high-expression patients, Figure 3B, 
HR=3.14) whereas 69% were classified as low-risk 
(98 patients; 48% Stage-II and 52% Stage-III). Fifteen of 
62 Stage-II patients were identified as high-risk according 
to the 5-gene classifier, only two of them being pT4. 
Low-risk patients had a five-year DFS rate of 80%, while 
that of high-risk patients was only 45%. Considering the 
stages separately, Stage-II low- and high-risk patients 
had five-year DFS rates of 89% and 52%, respectively 
(Figure 3C). In Stage-III, the five-year DFS rates were 
71% and 41% for low- and high-risk patients, respectively 
(Figure 3D). For DSS, the five-year life expectancy was 
clearly better for low-risk patients (84% versus 54%, 
HR=3.96, Figure 3F). High-grade tumors were more often 
classified as high-risk (P<0.0001) although the outcome 
may be biased by the high proportion of low-grade tumors 
(90.1%). High-risk has a statistical association with 
recurrence, time to recurrence and time to cancer-specific 
death (Supplementary table 1).
In the univariate analysis the 5-gene classifier was 
the strongest predictor of DFS (HR=3.14, 95% CI=1.72-
5.72, P<0.0001; Table 3). Using the 5-gene signature score 
as a continuous variable, the HR increased by 1.191 (95% 
CI=1.05-1.35, P=0.005) per unit increase in the SD of 
expression. Stage-III, high grade and lymphatic invasion 
were also associated with poor prognosis in univariate 
analyses of this cohort. These variables were included in 
the multivariate analysis (Table 3), in which the 5-gene 
classifier proved to be the only independent predictor of 
recurrence (HR=2.67, 95% CI=1.42-5, P=0.002).
Table 1. Patient demografics and clinical characteristics for the training set, in silico validation 
metacohort and real timeNAPCR validation set. (Continued )
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Figure 3: Prognostic information in the PCR independent validation. (A) Mean values of the 5-gene signature score according 
to patient recurrence in the PCR cohort of 142 samples (43 recurrent and 99 non-recurrent); t-test, P = 0.007.
(B-D) Kaplan-Meier plots for disease-free survival in all stages and Stage II or Stage III alone.
Considering only the 68 patients who did not receive adjuvant chemotherapy, the 5-gene classifier is associated with recurrence 
(HR = 3.79, 95% CI = 1.72 – 8.36, P = 0.001; Figure 3E).
(Continued )
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(F) Kaplan-Meier plots for disease-specific survival in all stages.
(G) Receiver operating characteristic curve describing the absence of predictive power for the recurrence of the collagen score.
(H) Using the 3rd tertile of the collagen score as a cut off, Kaplan-Meier survival plot shows that the collagen score provides no 
prognostic information in terms of disease-free survival in the PCR cohort. Thus, tumors with high collagen expression have the same 
outcome than low collagen tumors. The collagen score does not provide prognostic information. Higher collagen values are not associated 
with a worse outcome.
(I) Heatmap showing individual genes included in the classifier on the basis of their expression in the PCR cohort. The cut-off value 
obtained from the training dataset is represented by the change from green to red in the horizontal bar over the heatmap, which defines the 
two risk groups. The light grey and black boxes below the heatmap depict the samples identified as low or high collagen according to the 
collagen score (defined as the average expression of COL1A1 and COL3A1).
Our results suggest that the prognostic value is determined by the physiological status of the CAFs rather than their quantity. In these 
photomicrographs (J) we illustrate two colorectal tumors, both considered as “high stroma” because of the large quantity of desmoplasia 
(H-E staining), strong positivity for alpha smooth muscle actin (α-SMA), but reflecting a distinct transcriptomic status with respect to 
PDLIM3 staining. In the top right panel, CAFs display no staining for PDLIM3, one of the five genes of the classifier, and in addition, the 
tumor is classified as low-risk, according to the mRNA expression values of the five genes. Conversely, in the bottom right panel, CAFs 
display intense PDLIM3 staining, and the tumor is considered high-risk when considering the expression of all five genes.
(K) Our hypothesis is that the performance of the 5-gene classifier increases if considering specimens with a minimum number of 
fibroblasts. Samples with very low levels of fibroblasts will have a very poor representation of mRNA transcripts from fibroblast origin 
and will therefore be misclassified. As a proof of concept, we selected samples with a collagen score above the 25th percentile, excluding 
samples with poor collagen scores. This proof of concept can be done since low Collagen score tumors have the same outcome than high 
Collagen score tumors, as illustrated above. Additionally the proportion of stages and events is maintained in this subanalysis. Kaplan-Meier 
survival plots after excluding samples below the 25th percentile of the collagen score (n = 107 patients). The 5-gene classifier identifies two 
risks groups. Five-year DFS and DSS (not shown) survival rates according to the 5-gene signature score improved significantly excluding 
very low stroma patients.
Post-test probabilities confirmed the clinical utility 
of the 5-gene classifier for clinical decision-making, most 
notably in Stage-II patients (Table 2).
Physiological status rather than the quantity of 
CAFs confers prognostic value
We hypothesized that the prognostic value of the 
5-gene classifier reflects the physiological state of the 
CAFs rather than the number of fibroblasts in the tumor, 
and that samples with a very low percentage of CAFs 
might be misclassified since low levels of specific mRNAs 
would be present in the sample to be amplified among the 
large quantity of mRNA from other cell types. To test 
this, we obtained the most fibroblast-specific genes from 
GSE39396 (Supplementary figure 2A) and selected the two 
with the least variation in CAFs: COL1A1, and COL3A1. 
These genes were also associated specifically with CAFs 
from the breast [22]. We first demonstrated in vitro that 
there is a correlation between the number of fibroblasts in 
a sample and the expression of a collagen score (average 
expression of COL1A1, COL3A1) independently of the 
type of fibroblasts used (Supplementary Figure 2B, top 
panels). On the other hand, there was no correlation with 
the five genes of the classifier (Supplementary Figure 2B, 
bottom panels). Thus, the 5-gene classifier reflects the 
physiological state of the CAFs rather than the number 
of fibroblasts in a sample, and different CAF phenotypes 
are probably present in the same tumor, demonstrating the 
heterogeneity of the CAFs (Supplementary Figure 2C). 
In applying this assumption to tumor samples, we found 
that the performance of the ROC curve analysis of the 
collagen score for recurrence prediction was negligible, 
as illustrated in Figure 3G (AUC=0.48). Additionally, a 
high collagen score was not associated with recurrence 
(P=0.729) in our PCR cohort, in contrast to the 5-gene 
signature (P<0.0001). In GSE14333 and GSE33113, the 
collagen score was also not associated with recurrence 
(P=0.271 and P=0.369; there is an association for 
GSE17538). Regarding DFS time, the categorization of 
our cohort (PCR dataset) according to this collagen score 
(high and low categories, using the 3rd tertile as a cut 
off) were not related to clinical outcome (log-rank test, 
P=0.938; Figure 3H; P=0.785 using the median collagen 
score as cut off) and the same results were obtained in 
GSE14333 (P=0.525, Supplementary figure 2D). Collagen 
score as a continuous variable was not associated with 
DFS (Cox regression analysis, P=0.904). Thus, many high 
collagen samples were assigned as low-risk (Figure 3I). 
We also used immunohistochemical staining to evaluate 
PDLIM3 in high-stroma tumors quantified in H-E slides 
as the tumor/stroma ratio. As shown in Figure 3J, two 
high-stroma tumors, one classified as high-risk according 
to the 5-gene signature score, with intense α-SMA and 
PDLIM3 staining, and the other classified as low-risk 
according to our gene classifier, with intense α-SMA but 
without PDLIM3 positivity. Additionally hematoxylin-
eosin evaluation of stroma percentage in these samples 
reported no statistically significant differences between 
high stroma and low stroma groups (Kaplan-Meier 
Log Rank P = 0.123; Supplementary figure 3A). Since 
neither the quantity of collagen nor the stroma percentage 
provided consistent results regarding patient’s outcome, 
we confirmed by means a Kaplan-Meier analysis that the 
5-gene classifier can help to stratify highly desmoplastic 
tumours according to recurrence risk. Accordingly, using 
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the median Collagen score value as a cut off, in high 
collagen score samples, the 5-gene classifier clearly 
stratify patients according to risk (HR = 14.47, 
P = 0.00036), while in low collagen score samples did not 
(HR = 1.56, P = 0.344). This association is also illustrated 
in supplementary figures 3D-to-F stratifying patients 
in three groups according to Collagen score. The same 
trend is observed in dataset GSE17538 (supplementary 
figures 3G-to-I).
Additionally, we also investigate this fact in tumors 
regarding the tumor/stroma percentage assessed by 
hematoxylin-eosin staining. The 5-gene classifier also 
stratifies patients according to risk of relapse in the high 
stroma group (Supplementary figure 3J and K).
Performance of the 5-gene classifier excluding 
very low-stroma samples
We assumed, given the aforementioned results, that 
samples with a low collagen score might be misclassified 
due to the low level of CAFs in such specimens. To 
prove that, we excluded samples with collagen score < 
percentile 25. After discarding these samples, as proof 
of concept, the cohort comprised 107 patients, with same 
stages proportionality. As demonstrated by the Kaplan-
Meier curves (Figure 3K and supplementary figure 3B 
and C), the prognostic power of the 5-gene classifier is 
considerably superior. Therefore, as shown in Table 2, the 
assessment of the 5-gene classifier in samples relatively 
enriched in the stromal compartment differentiated 
patients into two risk groups. Actually, as illustrated in 
supplementary table 2 (ROC analysis), the predictive 
capability of the 5-gene classifier increases as we discard 
samples according to their collagen score. Thus a cohort 
containing samples with low collagen scores has a smaller 
AUC than a cohort enriched in samples containing 
higher collagen scores. The predictive power increases 
if Collagen is present, assuming that Collagen means 
fibroblasts. To corroborate this fact, we performed an 
interaction analysis between the collagen score and the 
5-gene classifier (Supplementary table 3) to demonstrate 
that the classifier has better predictive capabilities in 
samples with a higher collagen score.
Thus, selecting the 107 samples with high collagen 
scores (above the 25th percentile), the 5-gene classifier 
is still the strongest predictor of DFS in univariate 
and multivariate analyses (univariate: HR=6.87, 95% 
CI=3.02-15.49, P<0.0001; multivariate: HR=6.18, 95% 
CI=2.61- 14.6, P<0.0001; Table 3). Using the 5-gene 
signature score as a continuous variable, the HR increased 
by 1.36 (95% CI=1.18-1.57, P<0.0001) per unit increase 
in the SD of expression. The 5-gene signature was 
also significant in multivariate analysis when used as 
a continuous variable (HR=1.34, 95% CI=1.14-1.58, 
P<0.0001). In addition, post-test probabilities (Table 2) 
demonstrated the suitability of the 5-gene classifier for 
clinical practice.
DISCUSSION
In this paper, we report the development, validation 
and technique translation (RT-PCR) of a 5-gene classifier 
(including risk genes ULBP2, SLC7A2, PDLIM3, 
AMIGO2, and the protective gene CCL11) derived from a 
108-gene expression signature obtained from a microarray 
of deregulated genes in CAFs from colorectal cancer 
(Molecular Oncology 10.1016/j.molonc.2014.04.006). 
The 5-gene classifier is associated with the risk of relapse 
in patients with Stage II and Stage III CRC, regardless of 
the number of fibroblasts in the tumor specimen.
Not all the cells in a tumor are transcriptionally 
equivalent, and this is the case for CAFs. This is a 
consequence of the spatial location of each cell within the 
tumoral microecosystem, arising first from the particular 
relationships with other cells and other cell types, and 
second from the anatomical demarcation of a tumor and 
the mechanical and compressive forces exerted by the 
surrounding tissue (tensegrity) [23, 24]. Thus, recently, 
greater complexity has been revealed in the form of the 
considerable inter-tumoral heterogeneity of CAFs in the 
same organ as we and others have reported (Molecular 
Oncology 10.1016/j.molonc.2014.04.006) [25]. This 
suggests that the physiological status of CAFs may be 
more relevant in terms of the prognostic information 
provided than the number of fibroblasts itself. Therefore, 
a key concept in this study is that multiple, distinct 
biological responses are present to different extents 
within the CAFs of a given tumor, and the balance 
between these responses determines the good or bad 
prognostic value. Accordingly, our unsupervised analysis 
of the most variable genes in isolated CAFs clearly 
segregated two different patterns. The first comprises 
CAFs with the four overexpressed risk genes (AMIGO2, 
PDLIM3, ULBP2 and SLC7A2) and the underexpressed 
protective gene (CCL11). This subset is characterized by 
the overexpression of genes involved in the processes 
of migration, wound healing, angiogenesis, TGFβ 
responsive genes and downregulation of inflammatory 
genes. The second pattern involves a cluster enriched in 
inflammatory genes and the underexpression of the four 
risk genes. This is consistent with a previously observed 
stromal signature in breast cancer [26] in which samples 
from the good outcome cluster overexpressed a distinct 
set of immune-related genes. These good outcome tumors 
also have higher levels of fibroblasts expressing CXCL14, 
a chemokine that stimulates natural killer cell migration. 
Thus, individuals with this gene expression pattern may 
benefit from treatments targeting tumor cells via the 
immune response. In contrast, individuals with a poor 
outcome have higher levels of expression of stromal genes 
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involved in wound healing and angiogenesis. Several 
matrix metalloproteases are also strongly expressed.
The prognostic utility of stroma has recently been 
more widely reported although it is still not used routinely. 
Some authors have proposed using the percentage of 
tumor/stroma as a tool for classifying outcome in a variety 
of cancer types [27-30], even though these methods have 
some bias and do not take into account the intratumor 
heterogeneity with respect to transcriptomic status. In our 
cohort, the tumor stroma percentage did not associate 
with prognosis (Supplementary figure 3A), at least in 
the 106 cases available, although a trend is observed. 
Other authors evaluated the prognostic value of stroma 
or particular stromal cell types from the point of view 
of their transcriptional status [26, 31-33]. In relation to 
other CAF-specific genes our 5-gene classifier predicted 
Table 2. Post test recurrence probabilities values for the clinical value of the 5-gene signature score 

























































































To assess the potential usefulness of the 5-gene signature on clinical practice we evaluate the post test recurrence probabilities 
and we compared them to the a priori expected event proportion. For the in silico meta-cohort, considering all stages (expected 
recurrence value 32.5%) the post-test recurrence probability for the high-risk group increased to 56% and for the low-risk group 
the prediction was 22% probability of recurrence (34% absolute difference). Stratifying by stage, Stage I patients recurrence 
prevalence was 11%, but the post test probabilities increases to 20% for high-risk patients and decreases to 8% for low-risk 
patients. The 5-gene classifier had more potential clinical value for stages II-III. The absolute difference between positive post-
test probability and negative post-test probability was 37% for stage II and 28% for stage III patients. On the other hand, for 
PCR cohort, considering all stages (expected recurrence value 30%) the probability of recurrence bearing a tumour with high 
expression of the 5-gene classifier increased to 52% and decreased to 20% in low expression tumours. In stage II the expected 
probability of relapse is 19%. According to the 5-gene classifier, bearing a high expression tumour, this value increases to 47% 
and the value decreased to 11% in case of low-risk tumours. Thus, the absolute difference is 36%.
From the PCR cohort, considering samples with Collagen score > percentile25, the clinical value of the 5-gene 
classifier increases and is especially remarkable for stage II patients. As an example, selecting samples with Collagen score 
above percentile25 (n=107), the a priori probability of relapse of a stage II patient is 17%. Applying the 5-gene classifier, 
the probability of relapse will increase to 58% in case of bearing a high expression tumour, and will decrease to only 2% in 
case of a low expression tumour.
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Table 3. Univariate and multivariate analysis for DFS in quantitative RT-PCR validation dataset.
univariate multivariate
P value HR 95,0% CI P value HR 95,0% CI
Initial cohort (n=142)
Gender (female vs male) 0.07 0.55 0.29-1.04
Age >55 years 0.88 0.93 0.37-2.36
Stage (3 vs 2) 0.013 2.33 1.19-4.53 0.084 1.91 0.92-3.97
Location (rectum vs colon) 0.055 1.79 0.99-3.26
Grade (high vs low) 0.033 2.42 1.07-5.45 0.52 1.33 0.56-3.16
isolated nodes (<14 vs >14) 0.063 1.77 0.97-3.24
Lymphatic invasion (no) 0.049 0.53 0.28-0.99 0.37 0.73 0.37-1.45
Adjuvant chemotherapy (no) 0.083 1.71 0.93-3.14
Collagen score (high vs low) 0.689 0.88 0.46-1.66
5-gene classifier (high vs low) <0.0001 3.14 1.72-5.72 0.002 2.67 1.42-5
5-gene classifier (continuous, +1SD) 0.005 1.19 1.05-1.34 0.032* 1.16 1.01-1.32
>percentil25 Collagen score (n=107)
Gender (female vs male) 0.115 0.61 0.28-1.3
Age >55 years 0.7 0.79 0.24-2.6
Stage (3 vs 2) 0.014 2.76 1.23-6.21 0.363 1.57 0.67-3.69
Location (rectum vs colon) 0.003 2.99 1.44-6.23 0.009 2.76 1.3-5.9
Grade (high vs low) 0.023 2.82 1.15-6.93 0.78 1.14 0.45-2.94
isolated nodes (<14 vs >14) 0.067 1.95 0.95-4
Lymphatic invasion (no) 0.052 0.48 0.23-1
Adjuvant chemotherapy (no) 0.51 1.27 0.62-2.61
Collagen score (high vs low) 0.361 0.71 0.34-1.47
5-gene classifier (high vs low) <0.0001 6.87 3.02-15.49 <0.0001 6.18 2.61-14.6
5-gene classifier (continuous, +1SD) <0.0001 1.36 1.18-1.57 <0.0001* 1.34 1.14-1.58
*Multivariate analysis including Stage, location, grade and 5-gene signature score as a continuous variable.
recurrence with higher accuracy (Supplementary table 4). 
Interestingly, the 5-gene classifier is able to discriminate 
the a priori bad outcome highly desmoplastic tumors into 
two groups of risk.
More recently, many of the new molecular 
classifications have considered the stromal contribution 
to prognosis [34-36] [37] [38]. We only found overlap 
between two genes of our classifier and a recent molecular 
classification [38]. We were not surprised at this since the 
small number of genes in our classifier and its origin is 
based on the transcriptional changes between NCF and 
paired CAFs. By contrast, we found considerable overlap 
with the signature derive from other CAFs signatures from 
breast, lung, oral squamous cell carcinoma and esophagus 
[32, 39-41].
Integrating all the available information, it can be 
concluded that the stroma plays an extremely important 
role in the prognosis of colorectal cancer. Our results 
emphasize that the quantity of CAFs in a tumor is not as 
important as their transcriptomic or physiological status. 
Our 5-gene classifier, comprising genes almost exclusively 
expressed by CAFs, seems to reflect the physiological 
state of these myofibroblasts rather than just the number of 
fibroblasts in the tumor stroma. By contrast, the collagen 
score reflects the quantity of fibroblasts in a given sample 
and could be used to estimate the desmoplastic reaction. 
The lack of prognostic value of the collagen score with 
respect to the binary event (recurrence) and disease-free 
survival, leads us to suggest that the quantity of CAFs is 
not important for prognosis. With respect to the genes of 
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the classifier, four are considered to be risk genes, since 
their level of expression is positively correlated with the 
risk score, and CCL11 is considered to be a protective 
gene, its value being negatively correlated with the risk 
score. This is consistent with the levels of expression in 
NCFs and CAFs used to develop the differential signature 
(Molecular Oncology 10.1016/j.molonc.2014.04.006). 
This can be explained in two ways. One possibility is that 
fibroblasts in a tumor have heterogeneous transcriptomic 
profiles, although all of them are considered as CAFs, 
which, depending on their interaction with their 
surroundings (i.e., crosstalk with other cells), express 
these genes in a particular manner, leading to distinct CAF 
subpopulations coexisting in a tumor. The net balance of 
gene expression, rather than the quantity of fibroblasts, is 
what ultimately determines the prognostic value. In other 
words, the positional demarcation of a fibroblast in a tumor 
determines the crosstalk with its surroundings, and this can 
therefore be measured in terms of mRNA transcription. 
Another explanation for such CAF heterogeneity is that 
there are different origins [42].
Remarkably, the 5-gene classifier identifies Stage-II 
patients at high risk of relapse independently of the pT, 
and Stage-III patients at low risk of relapse. We found 
that the 5-year DFS rate was >90% in Stage-II patients 
who had a low 5-gene classifier score. This rate could 
be extended to Stage-III patients when selecting an 
appropriate biopsy from the surgical specimen to perform 
the test. This suggests that adjuvant chemotherapy would 
be of minimal benefit to this group of patients, especially 
those classified as Stage-II. Some authors have reported 
that the association of stromal gene expression with 
colorectal recurrence may explain the AJCC staging 
in which invasion is the critical feature [43]. Our study 
suggests that there is no statistical association with disease 
stage. Multivariate Cox regression analysis confirmed that 
the classifier, either as a dichotomized or a continuous 
variable, is an independent prognostic factor in Stage II/
III colorectal cancer. Additionally, the way in which the 
classifier has been developed enhances the biological 
relevance of it component genes, since no regression 
coefficients were used to obtain the score, and the genes 
were weighted equally.
The performance of the 5-gene classifier in 
independent, whole tumor-derived data sets and with two 
distinct technologies (microarray and PCR) indicates that 
although the prognostic power of the classifier is specific 
to tumor stroma, the signal can be detected when a 
minimal amount of stromal tissue is present in the sample. 
Moreover, prediction accuracy increases along with the 
quantity of stromal tissue, although this is not associated 
with a higher risk of relapse, as indicated by the lack of 
prognostic value of the collagen score.
The use and benefit of adjuvant chemotherapy in 
Stage-II patients is controversial [4], but the QUASAR 
study suggested that a subset of Stage-II patients with 
higher relapse risk may benefit from adjuvant treatment. 
Stage-III patients are routinely offered adjuvant 
chemotherapy but, despite treatment, approximately 
40% of them relapse [3]. Our 5-gene stromal classifier 
identifies subgroups with different recurrence risk even 
though there is a wider clinical margin between high-risk 
and low-risk patients in Stage-II compared with Stage-III 
patients.
CONCLUSIONS
In conclusion, using the 5-gene classifier in a 
clinical setting can provide more accurate information 
about the risk of recurrence than is possible from 
conventional clinicopathological criteria alone, and may 
facilitate the selection of high-risk Stage-II patients 
who would benefit from adjuvant therapy. Additionally, 
the predictive power of the 5-gene classifier is precise 
and accurate when selecting an area/biopsy from the 
surgical specimen that is relatively rich in tumor stroma 
(Figure 3K), as previously reported in prostate cancer 
[44]. The small number of genes comprising this classifier, 
and its validation in RT-PCR make it more amenable to 
clinical use than are large signatures. As is the case for 
other studies that have developed signatures, a limitation 
of this one is that it has only been possible to carry 
out a retrospective analysis of prospectively collected 
specimens. Future prospective studies are needed to 
confirm whether Stage-II patients at high-risk of relapse 
based on our classifier can achieve a better outcome if they 
receive adjuvant chemotherapy. Nonetheless the extensive 
in silico validation, and the translation and validation with 
PCR demonstrate the robustness of this 5-gene stromal 
classifier.
METHODS
Training and validation series: patients.
All public datasets were obtained from the GEO 
(Gene Expression Omnibus) and corresponded to the 
gene expression profile (GEP) of CRC patients obtained 
with the microarray platform (Affymetrix Human Genome 
U133Plus 2.0). GSE14333 was used as the training set. 
Datasets used for external validation corresponded to the 
GEP of whole tumor samples and GSE33113, GSE17538, 
and GSE14095. GSE31595 and GSE26892 were included 
in the meta-analysis. Datasets GSE18105 and GSE21510, 
containing GEP of LCM (laser capture microdissection) of 
epithelial cells from CRC patients, were used for negative 
validation of the stromal classifier. Table 1 illustrates the 
characteristics of the patients in the training set, the in 




Training and validation datasets obtained from 
GEO corresponded to whole tumor specimens. PCR 
validation dataset consisted in retrospective 142 frozen 
whole tumor samples stored at -80ºC and collected from 
the Hospital Universitari de Bellvitge Tumor Bank from 
1996 until 2001.
Classifier development
Figure 1 depicts the process by which the classifier 
was developed. The 5-gene classifier is derived from 
a 108-gene signature of differentially expressed genes 
(DEGs) between carcinoma-associated fibroblasts (CAFs) 
and paired normal colonic fibroblasts (NCFs) (Molecular 
Oncology 10.1016/j.molonc.2014.04.006).
In silico validation
The optimal predictive classifier was validated in 
three independent datasets (GSE17538, GSE14095 and 
GSE33113). GSE14333 and GSE17538 cohorts were 
partially overlapping. Cases duplicated in GSE14333 
and GSE17538 were excluded from validation. We 
also performed a meta-analysis, pooling GSE26892 
and GSE31595 with the aforementioned GSE17538 
and GSE33113 datasets (metacohort n=317; Table 1). 
In order to remove systematic biases between datasets, the 
expression levels of all genes were transformed to z-scores 
before pooling. A recurrence score was computed for each 
sample (see the Supplementary Methods).
Gene expression analysis by qRT-PCR in 
validation-PCR dataset
Frozen primary tumor tissue samples (n=142) from 
colorectal cancer patients (62 Stage-II, 80 Stage-III) were 
collected from the Hospital Universitari de Bellvitge 
Tumor Bank. Clinical and pathological data of these 
patients were obtained from the medicals records and 
reviewed for the study. RNA isolation and real-time PCR 
procedures are detailed in the Supplementary Methods.
RNA isolation and real time PCR procedures.
RNA was extracted from whole tumor tissue (both 
stroma and epithelial compartment) using TRIzol® reagent 
method and column purification using PureLink ™ RNA 
Mini Kit (Invitrogen). RNA quantity was determined 
by NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies Inc, Rockland, DE) and 100ng of total 
RNA was reverse-transcribed using M-MLV Reverse 
Transcriptase (Invitrogen) following manufacturer’s 
instructions. A 0.1µg equivalent of the corresponding 
cDNA was used for each quantitative PCR assay 
performed with the LightCycler® 480, SYBR Green I 
Master (Roche Applied Science, Mannheim, Germany). 
Primers were designed using Primer3 Input (http://primer3 
.wi.mit.edu) and predicted PCR product sequences were 
verified by using BLAST (http://www.ncbi.nlm.nih.gov/
blast). All primer sequences will be provided upon request. 
In every qRT-PCR reaction, a standard curve made from 
serial dilutions of a mix of RNA from different isolated 
fibroblasts was added to extrapolate for cDNA amount of 
the specific gene. To control for variation in RNA quantity 
between samples, the expression of each gene was further 
normalized to the geometric mean of two specifically 
selected reference genes. We aimed to use a reference gene 
in common at least between NCF, CAF and colorectal 
cell lines, attempting to prevent that the ratio tumor/
stroma affected the normalization of the classifier genes. 
Different possible housekeeping genes (ACTB, PMM1, 
GAPDH, B2M, HPRT1, PPIA, IPO8, RSP13) were tested 
for stability in 10 colon cancer tissue samples as well as in 
different colorectal cancer cell lines and in a mix of RNA 
from NCF and CAF and in mixes of NCF, CAF and CRC 
cell lines. Using RefFinder, a web-base tool (http://leonxie 
.com/referencegene.php) which integrates different online 
applications (Normfinder [45], geNorm [46], BestKeeper 
[47] and ΔCt [48]), candidate reference genes mentioned 
above, were compared and ranked to select those with 
more stability. ACTB and PMM1 were the most stable 
genes between all different samples tested. Normalized 
values were further log transformed and standardized.
Recurrence score estimation
A recurrence score for a given patient was calculated 
as the sum of the standardized value of each gene. No 
gene level parameter estimation was performed and 
coefficients were established as 1 for overexpressed 
genes in CAF vs. NCF (PDLIM3, SLC7A2, ULBP2 and 
AMIGO2; risk genes) and -1 for underexpressed gene in 
CAF vs. NCF (CCL11, protective gene). Patients in each 
cohort were classified according to their 5-gene expression 
score as having a high-risk gene signature or a low-risk 
gene signature. As a cut off we used the 3rd tertile of the 
classifier score (percentile 66.66) in the training set. Then 
low-risk patients were define as those with score < 1.1328 
and high-risk patients as those above 1.1328. The same cut 
off value was applied to all other validation cohorts
Statistical analysis
Kaplan-Meier survival analyses with the log-rank 
test were used to estimate five-year disease-free survival 
(DFS) and disease-specific survival (DSS) rates in the 
different cohorts tested. DFS and DSS were defined as the 
time until an event (relapse, locoregional or metastasis, 
and death from CRC, respectively), and patients were 
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censored at last follow-up, cancer-related death or 
treatment-related death. In all datasets, a minimum three-
year follow-up was required for patients without tumor 
recurrence. More detailed information is provided in 
supplementary statistical methods.
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